SI-BONE (NASDAQ:SIBN) Hits New 52-Week Low at $14.84

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $14.84 and last traded at $15.08, with a volume of 18134 shares. The stock had previously closed at $14.97.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Truist Financial reissued a "buy" rating and issued a $24.00 price target (down previously from $26.00) on shares of SI-BONE in a research note on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 27th. Morgan Stanley lifted their target price on SI-BONE from $25.00 to $26.00 and gave the company an "overweight" rating in a research note on Tuesday, February 27th. Needham & Company LLC reiterated a "buy" rating and set a $27.00 price target on shares of SI-BONE in a report on Wednesday, April 3rd. Finally, Piper Sandler assumed coverage on SI-BONE in a report on Thursday, March 28th. They set an "overweight" rating and a $25.00 price target for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE presently has an average rating of "Buy" and an average price target of $26.67.

SI-BONE Trading Up 2.0 %

The firm has a market capitalization of $626.99 million, a P/E ratio of -13.33 and a beta of 1.20. The company has a quick ratio of 8.15, a current ratio of 9.01 and a debt-to-equity ratio of 0.21. The business has a 50-day moving average price of $17.74 and a 200-day moving average price of $18.52.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. The firm had revenue of $38.86 million for the quarter, compared to analysts' expectations of $38.60 million. SI-BONE had a negative return on equity of 28.22% and a negative net margin of 31.20%. Analysts anticipate that SI-BONE, Inc. will post -0.98 earnings per share for the current year.

Insider Activity at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 2,425 shares of the stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total value of $37,466.25. Following the sale, the chief financial officer now directly owns 205,516 shares in the company, valued at $3,175,222.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Anthony J. Recupero sold 3,330 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $16.82, for a total transaction of $56,010.60. Following the completion of the sale, the insider now owns 255,760 shares of the company's stock, valued at $4,301,883.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Anshul Maheshwari sold 2,425 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total transaction of $37,466.25. Following the sale, the chief financial officer now directly owns 205,516 shares of the company's stock, valued at approximately $3,175,222.20. The disclosure for this sale can be found here. Insiders have sold 11,562 shares of company stock worth $185,285 in the last ninety days. Company insiders own 5.40% of the company's stock.

Institutional Investors Weigh In On SI-BONE

Large investors have recently made changes to their positions in the stock. Quarry LP acquired a new stake in SI-BONE in the fourth quarter valued at $28,000. Coppell Advisory Solutions LLC acquired a new stake in SI-BONE in the second quarter valued at $50,000. FMR LLC lifted its stake in SI-BONE by 28.7% in the first quarter. FMR LLC now owns 2,160 shares of the company's stock valued at $42,000 after acquiring an additional 482 shares during the last quarter. Comerica Bank acquired a new stake in SI-BONE in the third quarter valued at $47,000. Finally, RiverPark Advisors LLC acquired a new stake in SI-BONE in the third quarter valued at $55,000. Institutional investors own 98.11% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.